FTC moves to block Edwards' JenaValve acquisition
The Federal Trade Commission has moved to block Edwards Lifesciences' planned acquisition of JenaValve Technology, citing concerns that the deal threatens to reduce competition in the market for devices to treat aortic regurgitation.
The agency alleged that over two days in July 2024, Edwards signed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring transcatheter aortic valve replacement devices to market to treat the potentially fatal heart condition. Edwards closed the acquisition of JC Medical in August 2024.
The FTC said Edwards' proposed $945 million acquisition of JenaValve would combine the only two companies conducting U.S. clinical trials for a TAVR aortic regurgitation, or TAVR-AR, device.
'The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for consumers,' the agency stated in a federal court complaint.
The commission voted 3-0 to issue an administrative complaint and seek a temporary restraining order and a preliminary injunction to halt the transaction pending an administrative proceeding. The complaint and injunction request were filed in the U.S. District Court for the District of Columbia.
JenaValve is poised to become the first company to bring a TAVR-AR device, called Trilogy, to the U.S. market, the FTC said. Food and Drug Administration approval of a TAVR-AR device by another company besides Edwards and JenaValve is not expected in the foreseeable future.
'The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards' JC Medical subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs,' Daniel Guarnera, director of the FTC's Bureau of Competition, said in the agency's Wednesday statement.
Edwards' stance
Edwards said Wednesday that it disagrees with the FTC's decision and believes it will limit the treatment options for patients with aortic regurgitation. Edwards argued that the acquisition will actually 'accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR.'
The company plans to continue to pursue regulatory approval for the deal and expects a final determination by the end of the first quarter of 2026.
JenaValve also said that it remains committed to completing the transaction and is confident in the rationale for the merger and the value it will bring to patients. The company intends to join Edwards to defend the case in court.
Edwards increased its forecast for 2025 adjusted earnings per share to the high end of a range of $2.45 to $2.55, up from the high end of a range of $2.40 to $2.50, to reflect the impact of the FTC's action. The company said there is no impact to revenue guidance.
Edwards agreed to pay $1.2 billion combined in July 2024 to buy JenaValve and Endotronix, which makes an implantable heart failure sensor. With the Endotronix transaction completed, Edwards was expecting the JenaValve deal to close in the middle of this year.
Recommended Reading
Edwards shrugs off tariffs, backs 2025 profit forecast
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Trump to sign order easing path for private assets in 401(k)s, Bloomberg News reports
(Reuters) -U.S. President Donald Trump will sign an executive order on Thursday that aims to allow private equity, real estate, cryptocurrency and other alternative assets in 401(k)s, Bloomberg News reported on Thursday, citing a person familiar with the plans. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
OpenAI Opens Up With New GPT-OSS Models
OpenAI, backed by Microsoft (MSFT), just stepped deeper into the open-source world with two new open-weight AI modelsgpt-oss-120b and gpt-oss-20btaking direct aim at Google's (NASDAQ:GOOG) Gemini CLI and DeepSeek's (DEEPSEEK) R1. The bigger model, 120b, is designed to run in data centers or on high-end hardware with Nvidia (NVDA) H100 GPUs, while the smaller 20b model works on most desktops and laptops. According to Amazon Web Services (NASDAQ:AMZN), the 120b model running on Bedrock is up to 3x more price-performant than Gemini, 5x better than DeepSeek-R1, and even 2x better than OpenAI's own o4 model. At this scale, giving developers open access is a game-changer, said Atul Deo from AWS, calling it a major step forward for enterprise AI. The models are released under the Apache 2.0 license, so developerseven commercial teamscan use them freely without worrying about copyright or patents. The training data and model code however are not publicly available, so these models are open-weight, but not available through Hugging Face, GitHub, and is signaling it's ready to compete openlynot just behind closed APIs. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Analysis-Trump may look like he's winning the trade war, but hurdles remain
By Andrea Shalal WASHINGTON (Reuters) -At a glance, U.S. President Donald Trump appears to be winning the trade war he unleashed after returning to the White House in January, bending major trading partners to his will, imposing double-digit tariff rates on nearly all imports, narrowing the trade deficit, and raking in tens of billions of dollars a month in much-needed cash for federal government coffers. Significant hurdles remain, however, including whether U.S. trading partners will make good on investment and goods-purchase commitments, how much tariffs will drive up inflation or stymie demand and growth, and whether the courts allow many of his ad-hoc levies to stand. On inauguration day, the effective U.S. tariff rate was about 2.5%. It has since jumped to somewhere between 17% and 19%, according to a range of estimates. The Atlantic Council estimates it will edge closer to 20%, the highest in a century, with higher duties taking effect on Thursday. Trading partners have largely refrained from retaliatory tariffs, sparing the global economy from a more painful tit-for-tat trade war. Data on Tuesday showed a 16% narrowing of the U.S. trade deficit in June, while the U.S. trade gap with China shrank to its smallest in more than 21 years. American consumers have shown themselves to be more resilient than expected, but some recent data indicate the tariffs are already affecting jobs, growth and inflation. "The question is, what does winning mean?" said Josh Lipsky, who heads economic studies at the Atlantic Council. "He's raising tariffs on the rest of the world and avoiding a retaliatory trade war far easier than even he anticipated, but the bigger question is what effect does that have on the U.S. economy." Michael Strain, head of economic policy studies at the conservative American Enterprise Institute, said Trump's geopolitical victories could prove hollow. "In a geopolitical sense, Trump's obviously getting tons of concessions from other countries, but in an economic sense, he's not winning the trade war," he said. "What we're seeing is that he is more willing to inflict economic harm on Americans than other countries are willing to inflict on their nations. And I think of that as losing." Kelly Ann Shaw, a White House trade adviser during Trump's first term who is now a partner at Akin Gump Strauss Hauer & Feld, said a still-strong economy and near-record-high stock prices "support a more aggressive tariff strategy." But Trump's tariffs, tax cuts, deregulation and policies to boost energy production would take time to play out. "I think history will judge these policies, but he is the first president in my lifetime to make major changes to the global trading system," she added. DEALS SO FAR Trump has concluded eight framework agreements with the European Union, Japan, Britain, South Korea, Vietnam, Indonesia, Pakistan and the Philippines that impose tariffs on their goods ranging from 10% to 20%. That's well short of the "90 deals in 90 days" administration officials had touted in April, but they account for some 40% of U.S. trade flows. Adding in China, currently saddled with a 30% levy on its goods but likely to win another reprieve from even higher tariffs before an August 12 deadline, would raise that to nearly 54%. Deals aside, many of Trump's tariff actions have been mercurial. On Wednesday he ratcheted up pressure on India, doubling new tariffs on goods from there to 50% from 25% because of its imports of oil from Russia. The same rate is in store for goods from Brazil, after Trump complained about its prosecution of former leader Jair Bolsonaro, a Trump ally. And Switzerland, which Trump had previously praised, is facing 39% tariffs after a conversation between its leader and Trump derailed a deal. Ryan Majerus, a trade lawyer who worked in both the first Trump administration and the Biden government, said what's been announced so far fails to address "longstanding, politically entrenched trade issues" that have bothered U.S. policymakers for decades, and getting there would likely take "months, if not years." He also noted they lack specific enforcement mechanisms for the big investments announced, including $550 billion for Japan and $600 billion for the EU. PROMISES AND RISKS Critics lit into European Commission President Ursula von der Leyen after she agreed to a 15% tariff during a surprise meeting with Trump during his trip to Scotland last month, while gaining little in return. The deal frustrated winemakers and farmers, who had sought a zero-for-zero tariff. Francois-Xavier Huard, head of France's FNIL national dairy sector federation, said 15% was better than the threatened 30%, but would still cost dairy farmers millions of euros. European experts say von der Leyen's move did avert higher tariffs, calmed tensions with Trump, averting potentially higher duties on semiconductors, pharmaceuticals and cars, while making largely symbolic pledges to buy $750 billion of U.S. strategic goods and invest over $600 billion. Meeting those pledges will fall to individual EU members and companies, and cannot be mandated by Brussels, trade experts and analysts note. U.S. officials insist Trump can re-impose higher tariffs if he believes the EU, Japan or others are not honoring their commitments. But it remains unclear how that would be policed. And history offers a caution. China, with its state-run economy, never met its modest purchase agreements under Trump's Phase 1 U.S.-China trade deal. Holding it to account proved difficult for the subsequent Biden administration. "All of it is untested. The EU, Japan and South Korea are going to have to figure out how to operationalize this," Shaw said. "It's not just government purchases. It's getting the private sector motivated to either make investments or back loans, or to purchase certain commodities." And lastly, the main premise for the tariffs Trump has imposed unilaterally faces legal challenges. His legal team met with stiff questioning during appellate court oral arguments over his novel use of the 1977 International Emergency Economic Powers Act, historically used for sanctioning enemies or freezing their assets, to justify his tariffs. A ruling could come any time and regardless of the outcome seems destined to be settled ultimately by the Supreme Court. Sign in to access your portfolio
